• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ZLD
Click for more information
0.78% 64.5¢

ZELIRA THERAPEUTICS LIMITED - Announcements

Market Cap $7.716M  ! watchlist Created with Sketch. Add to my watchlist

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company... Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
ZLD Zelda Partners with Ilera HealthCarePRICE SENSITIVE12/03/19
ZLD Aus Patent For Novel Prognostic Marker for Breast CancerPRICE SENSITIVE06/03/19
ZLD Appendix 4D & FY19 Interim Financial ReportPRICE SENSITIVE22/02/19
ZLD Appendix 4C - quarterlyPRICE SENSITIVE30/01/19
ZLD December 2018 Quarterly Report and Board TransitionPRICE SENSITIVE30/01/19
ZLD Response to ASX Price and Volume QueryPRICE SENSITIVE08/01/19
ZLD ZLD to Invest in Development of Oral Spray FormulationsPRICE SENSITIVE06/12/18
ZLD SUD: SUDA Enters Agreement To Develop Cannabinoid SprayPRICE SENSITIVE06/12/18
ZLD Opioid reduction clinical trial with St Vincent's HospitalPRICE SENSITIVE26/11/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE31/10/18
ZLD September 2018 Quarterly ReportPRICE SENSITIVE31/10/18
ZLD Zelda Focuses Clinical Trial ActivityPRICE SENSITIVE11/10/18
ZLD US Autism Observational Study UnderwayPRICE SENSITIVE10/10/18
ZLD First Patient Dosed in Zelda Insomnia TrialPRICE SENSITIVE26/09/18
ZLD Zelda Forms New Partnership to Access German MarketPRICE SENSITIVE04/09/18
ZLD Appendix 4E & Financial StatementsPRICE SENSITIVE31/08/18
ZLD June 2018 Quarterly ReportPRICE SENSITIVE30/07/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE30/07/18
ZLD Commencement of New Managing DirectorPRICE SENSITIVE16/07/18 download Created with Sketch. 159.29KB
ZLD Appointment of Managing DirectorPRICE SENSITIVE22/05/18 download Created with Sketch. 124.53KB
ZLD March 2018 Quarterly ReportPRICE SENSITIVE30/04/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
ZLD Insomnia Clinical Trial Update-Patient Recruitment CompletedPRICE SENSITIVE23/04/18
ZLD Expansion of Pancreatic Cancer Research ProgrammePRICE SENSITIVE06/03/18
ZLD Appendix 4D & FY18 Interim Financial ReportPRICE SENSITIVE27/02/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
ZLD Zelda joins with US Children's Hospital for autism studyPRICE SENSITIVE11/12/17
ZLD Trading HaltPRICE SENSITIVE08/12/17
ZLD Response to ASX Aware QueryPRICE SENSITIVE05/12/17
ZLD Australian Regulators Approve Zelda Insomnia Clinical TrialPRICE SENSITIVE29/11/17
ZLD Response to ASX Price and Volume QueryPRICE SENSITIVE22/11/17
ZLD Trading HaltPRICE SENSITIVE21/11/17
ZLD Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
ZLD Successful Results in Autism Observation TrialPRICE SENSITIVE18/09/17
ZLD Appendix 4E & Financial StatementsPRICE SENSITIVE31/08/17
ZLD Expansion of Breast Cancer Research CollaborationPRICE SENSITIVE31/07/17
ZLD Appendix 4C - quarterlyPRICE SENSITIVE28/07/17
ZLD ENT:Acquisition of prospective Au& Cu/Zn Murchison TenementsPRICE SENSITIVE26/07/17
ZLD Zelda Enters into Strategic Agreement with Knop LaboratoriesPRICE SENSITIVE15/06/17
ZLD Positive Results From Pre-Clinical Breast Cancer StudiesPRICE SENSITIVE02/06/17
ZLD March 2017 Quarterly ReportPRICE SENSITIVE28/04/17
ZLD Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
ZLD Clinical Research Programme to Expand to Include AutismPRICE SENSITIVE19/04/17
ZLD Cleansing ProspectusPRICE SENSITIVE03/04/17
ZLD Zelda Successfully Completes Capital RaisingPRICE SENSITIVE30/03/17
ZLD Trading HaltPRICE SENSITIVE28/03/17
ZLD Zelda Enters Strategic Partnership with CannPalPRICE SENSITIVE27/03/17
ZLD Clinical Trials to Commence in ChilePRICE SENSITIVE23/03/17
ZLD New Licence AgreementPRICE SENSITIVE21/03/17
ZLD Appendix 4D & FY17 Interim Financial ReportPRICE SENSITIVE27/02/17
ZLD Quarterly Report and Appendix 4CPRICE SENSITIVE31/01/17
ZLD Zelda to Test Formulations Against Pancreatic CancerPRICE SENSITIVE20/12/16
ZLD Sleep Disorder Clinical Trials UpdatePRICE SENSITIVE12/12/16
ZLD Collaboration Agreement with Telethon Kids InstitutePRICE SENSITIVE05/12/16
ZLD Significant Anti-Cancer Effect Observed in StudiesPRICE SENSITIVE30/11/16
ZLD Zelda expands its Intellectual Property portfolioPRICE SENSITIVE25/11/16
ZLD OpenBriefing Recording with Dr Stewart WasherPRICE SENSITIVE23/11/16
ZLD Reinstatement to Official Quotation - 22 November 2016PRICE SENSITIVE18/11/16
ZLD Suspension from Official Quotation-GLN.AX PRICE SENSITIVE25/07/16
ZLD Prospectus-GLN.AX PRICE SENSITIVE12/07/16
ZLD Consolidation/Split - GLN-GLN.AX PRICE SENSITIVE28/06/16
ZLD Successful Completion of Pre-IPO Capital Raise-GLN.AX PRICE SENSITIVE30/05/16
ZLD Quarterly Activities Report-GLN.AX PRICE SENSITIVE29/04/16
ZLD Quarterly Cashflow Report-GLN.AX PRICE SENSITIVE29/04/16
ZLD Quarterly Cashflow ReportPRICE SENSITIVE29/01/16
ZLD Quarterly Activities ReportPRICE SENSITIVE29/01/16
ZLD Gleneagle to Acquire Zelda Therapeutics Pty LtdPRICE SENSITIVE09/12/15
ZLD Trading HaltPRICE SENSITIVE07/12/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE29/10/15
ZLD Quarterly Activities ReportPRICE SENSITIVE29/10/15
ZLD Capital RaisingPRICE SENSITIVE13/10/15
ZLD Myostin Merger not ProceedingPRICE SENSITIVE01/09/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE31/07/15
ZLD Quarterly Activities ReportPRICE SENSITIVE31/07/15
ZLD Quarterly Activities ReportPRICE SENSITIVE29/04/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE29/04/15
ZLD Gleneagle to Merge with MyostinTherapeutics Pty LtdPRICE SENSITIVE16/03/15
ZLD Trading HaltPRICE SENSITIVE11/03/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE29/01/15
ZLD Quarterly Activities ReportPRICE SENSITIVE29/01/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE30/10/14
ZLD Quarterly Activities ReportPRICE SENSITIVE30/10/14
ZLD Response to ASX Price QueryPRICE SENSITIVE09/09/14
ZLD Quarterly Cashflow ReportPRICE SENSITIVE28/07/14
ZLD Quarterly Activities ReportPRICE SENSITIVE28/07/14
ZLDQuarterly Cashflow ReportPRICE SENSITIVE30/04/14
ZLDQuarterly Activities ReportPRICE SENSITIVE30/04/14
ZLDQuarterly Activities ReportPRICE SENSITIVE28/01/14
ZLDQuarterly Cashflow ReportPRICE SENSITIVE28/01/14
ZLDQuarterly Activities ReportPRICE SENSITIVE29/10/13
ZLDQuarterly Cashflow ReportPRICE SENSITIVE29/10/13
ZLDAcquisition of Cuddingwarra TenementsPRICE SENSITIVE12/08/13
ZLDQuarterly Activities ReportPRICE SENSITIVE31/07/13
ZLDQuarterly Cashflow ReportPRICE SENSITIVE31/07/13
ZLDAssay Results - Peak HillPRICE SENSITIVE30/07/13
ZLDQuarterly Cashflow ReportPRICE SENSITIVE29/04/13
ZLDQuarterly Activities ReportPRICE SENSITIVE29/04/13
ZLDQuarterly Cashflow ReportPRICE SENSITIVE30/01/13
ZLDQuarterly Activities ReportPRICE SENSITIVE30/01/13
ZLDQuarterly Activities ReportPRICE SENSITIVE29/10/12
ZLD Zelda Partners with Ilera HealthCare
12/03/19PRICE SENSITIVE
ZLD Aus Patent For Novel Prognostic Marker for Breast Cancer
06/03/19PRICE SENSITIVE
ZLD Appendix 4D & FY19 Interim Financial Report
22/02/19PRICE SENSITIVE
ZLD Appendix 4C - quarterly
30/01/19PRICE SENSITIVE
ZLD December 2018 Quarterly Report and Board Transition
30/01/19PRICE SENSITIVE
ZLD Response to ASX Price and Volume Query
08/01/19PRICE SENSITIVE
ZLD ZLD to Invest in Development of Oral Spray Formulations
06/12/18PRICE SENSITIVE
ZLD SUD: SUDA Enters Agreement To Develop Cannabinoid Spray
06/12/18PRICE SENSITIVE
ZLD Opioid reduction clinical trial with St Vincent's Hospital
26/11/18PRICE SENSITIVE
ZLD Appendix 4C - quarterly
31/10/18PRICE SENSITIVE
ZLD September 2018 Quarterly Report
31/10/18PRICE SENSITIVE
ZLD Zelda Focuses Clinical Trial Activity
11/10/18PRICE SENSITIVE
ZLD US Autism Observational Study Underway
10/10/18PRICE SENSITIVE
ZLD First Patient Dosed in Zelda Insomnia Trial
26/09/18PRICE SENSITIVE
ZLD Zelda Forms New Partnership to Access German Market
04/09/18PRICE SENSITIVE
ZLD Appendix 4E & Financial Statements
31/08/18PRICE SENSITIVE
ZLD June 2018 Quarterly Report
30/07/18PRICE SENSITIVE
ZLD Appendix 4C - quarterly
30/07/18PRICE SENSITIVE
ZLD Commencement of New Managing Director
16/07/18PRICE SENSITIVE download Created with Sketch. 159.29KB
ZLD Appointment of Managing Director
22/05/18PRICE SENSITIVE download Created with Sketch. 124.53KB
ZLD March 2018 Quarterly Report
30/04/18PRICE SENSITIVE
ZLD Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
ZLD Insomnia Clinical Trial Update-Patient Recruitment Completed
23/04/18PRICE SENSITIVE
ZLD Expansion of Pancreatic Cancer Research Programme
06/03/18PRICE SENSITIVE
ZLD Appendix 4D & FY18 Interim Financial Report
27/02/18PRICE SENSITIVE
ZLD Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
ZLD Zelda joins with US Children's Hospital for autism study
11/12/17PRICE SENSITIVE
ZLD Trading Halt
08/12/17PRICE SENSITIVE
ZLD Response to ASX Aware Query
05/12/17PRICE SENSITIVE
ZLD Australian Regulators Approve Zelda Insomnia Clinical Trial
29/11/17PRICE SENSITIVE
ZLD Response to ASX Price and Volume Query
22/11/17PRICE SENSITIVE
ZLD Trading Halt
21/11/17PRICE SENSITIVE
ZLD Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
ZLD Successful Results in Autism Observation Trial
18/09/17PRICE SENSITIVE
ZLD Appendix 4E & Financial Statements
31/08/17PRICE SENSITIVE
ZLD Expansion of Breast Cancer Research Collaboration
31/07/17PRICE SENSITIVE
ZLD Appendix 4C - quarterly
28/07/17PRICE SENSITIVE
ZLD ENT:Acquisition of prospective Au& Cu/Zn Murchison Tenements
26/07/17PRICE SENSITIVE
ZLD Zelda Enters into Strategic Agreement with Knop Laboratories
15/06/17PRICE SENSITIVE
ZLD Positive Results From Pre-Clinical Breast Cancer Studies
02/06/17PRICE SENSITIVE
ZLD March 2017 Quarterly Report
28/04/17PRICE SENSITIVE
ZLD Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
ZLD Clinical Research Programme to Expand to Include Autism
19/04/17PRICE SENSITIVE
ZLD Cleansing Prospectus
03/04/17PRICE SENSITIVE
ZLD Zelda Successfully Completes Capital Raising
30/03/17PRICE SENSITIVE
ZLD Trading Halt
28/03/17PRICE SENSITIVE
ZLD Zelda Enters Strategic Partnership with CannPal
27/03/17PRICE SENSITIVE
ZLD Clinical Trials to Commence in Chile
23/03/17PRICE SENSITIVE
ZLD New Licence Agreement
21/03/17PRICE SENSITIVE
ZLD Appendix 4D & FY17 Interim Financial Report
27/02/17PRICE SENSITIVE
ZLD Quarterly Report and Appendix 4C
31/01/17PRICE SENSITIVE
ZLD Zelda to Test Formulations Against Pancreatic Cancer
20/12/16PRICE SENSITIVE
ZLD Sleep Disorder Clinical Trials Update
12/12/16PRICE SENSITIVE
ZLD Collaboration Agreement with Telethon Kids Institute
05/12/16PRICE SENSITIVE
ZLD Significant Anti-Cancer Effect Observed in Studies
30/11/16PRICE SENSITIVE
ZLD Zelda expands its Intellectual Property portfolio
25/11/16PRICE SENSITIVE
ZLD OpenBriefing Recording with Dr Stewart Washer
23/11/16PRICE SENSITIVE
ZLD Reinstatement to Official Quotation - 22 November 2016
18/11/16PRICE SENSITIVE
ZLD Suspension from Official Quotation-GLN.AX
25/07/16PRICE SENSITIVE
ZLD Prospectus-GLN.AX
12/07/16PRICE SENSITIVE
ZLD Consolidation/Split - GLN-GLN.AX
28/06/16PRICE SENSITIVE
ZLD Successful Completion of Pre-IPO Capital Raise-GLN.AX
30/05/16PRICE SENSITIVE
ZLD Quarterly Activities Report-GLN.AX
29/04/16PRICE SENSITIVE
ZLD Quarterly Cashflow Report-GLN.AX
29/04/16PRICE SENSITIVE
ZLD Quarterly Cashflow Report
29/01/16PRICE SENSITIVE
ZLD Quarterly Activities Report
29/01/16PRICE SENSITIVE
ZLD Gleneagle to Acquire Zelda Therapeutics Pty Ltd
09/12/15PRICE SENSITIVE
ZLD Trading Halt
07/12/15PRICE SENSITIVE
ZLD Quarterly Cashflow Report
29/10/15PRICE SENSITIVE
ZLD Quarterly Activities Report
29/10/15PRICE SENSITIVE
ZLD Capital Raising
13/10/15PRICE SENSITIVE
ZLD Myostin Merger not Proceeding
01/09/15PRICE SENSITIVE
ZLD Quarterly Cashflow Report
31/07/15PRICE SENSITIVE
ZLD Quarterly Activities Report
31/07/15PRICE SENSITIVE
ZLD Quarterly Activities Report
29/04/15PRICE SENSITIVE
ZLD Quarterly Cashflow Report
29/04/15PRICE SENSITIVE
ZLD Gleneagle to Merge with MyostinTherapeutics Pty Ltd
16/03/15PRICE SENSITIVE
ZLD Trading Halt
11/03/15PRICE SENSITIVE
ZLD Quarterly Cashflow Report
29/01/15PRICE SENSITIVE
ZLD Quarterly Activities Report
29/01/15PRICE SENSITIVE
ZLD Quarterly Cashflow Report
30/10/14PRICE SENSITIVE
ZLD Quarterly Activities Report
30/10/14PRICE SENSITIVE
ZLD Response to ASX Price Query
09/09/14PRICE SENSITIVE
ZLD Quarterly Cashflow Report
28/07/14PRICE SENSITIVE
ZLD Quarterly Activities Report
28/07/14PRICE SENSITIVE
ZLDQuarterly Cashflow Report
30/04/14PRICE SENSITIVE
ZLDQuarterly Activities Report
30/04/14PRICE SENSITIVE
ZLDQuarterly Activities Report
28/01/14PRICE SENSITIVE
ZLDQuarterly Cashflow Report
28/01/14PRICE SENSITIVE
ZLDQuarterly Activities Report
29/10/13PRICE SENSITIVE
ZLDQuarterly Cashflow Report
29/10/13PRICE SENSITIVE
ZLDAcquisition of Cuddingwarra Tenements
12/08/13PRICE SENSITIVE
ZLDQuarterly Activities Report
31/07/13PRICE SENSITIVE
ZLDQuarterly Cashflow Report
31/07/13PRICE SENSITIVE
ZLDAssay Results - Peak Hill
30/07/13PRICE SENSITIVE
ZLDQuarterly Cashflow Report
29/04/13PRICE SENSITIVE
ZLDQuarterly Activities Report
29/04/13PRICE SENSITIVE
ZLDQuarterly Cashflow Report
30/01/13PRICE SENSITIVE
ZLDQuarterly Activities Report
30/01/13PRICE SENSITIVE
ZLDQuarterly Activities Report
29/10/12PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
64.5¢ 		Change
0.005(0.78%) 		Mkt cap ! $7.716M
Open High Low Value Volume
64.0¢ 64.5¢ 64.0¢ $1.494K 2.335K

Buyers (Bids)

No. Vol. Price($)
1 1982 65.0¢
 

Sellers (Offers)

Price($) Vol. No.
70.0¢ 27714 1
View Market Depth
Last trade - 15.33pm 25/11/2024 (20 minute delay) ?
ZLD (ASX) Chart

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Tambourah chases gold veins and mineralisation extension with drilling Tambourah Metals Ltd has discovered two high-grade gold veins through a diamond drilling program in Western Australia
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.